Drug intelligence / Profile preview

PL-4902

Development stage: Preclinical
Lead developer: Jiangsu ProteLight Pharmaceutical & Biotechnology
Modality: Peptides
Administration: Injection

Overview

PL-4902 is a synthetic peptide drug candidate developed by Protelight Pharmaceuticals. It is designed to target bacterial cell membranes and is being investigated for the treatment of systemic and pulmonary infections, particularly infectious lung disorders. The drug is administered via injection and remains in the preclinical stage of development as of March 2025. Its primary mechanism involves disrupting or interacting with bacterial cell membranes, which may lead to antibacterial effects against pathogens responsible for respiratory and systemic infections[1][7].

Beyond the preview

Go deeper on PL-4902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-4902.

Explore the full profile